ENZYMEBIOSYSTEMS (ENZB) financial statements (2020 and earlier)

Company profile

Business Address 8440 W. LAKE MEAD
LAS VEGAS, NV 89128
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

6/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41
Cash and cash equivalents41
Prepaid expense3
Total current assets:44
Noncurrent Assets
TOTAL ASSETS:44
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4
Accounts payable0
Accrued liabilities4
Total current liabilities:4
Noncurrent Liabilities
Total liabilities:4
Stockholders' equity
Stockholders' equity attributable to parent40
Preferred stock3
Common stock17
Additional paid in capital1,243
Accumulated deficit(1,222)
Total stockholders' equity:40
TOTAL LIABILITIES AND EQUITY:44

Income statement (P&L) ($ in thousands)

6/30/2017
Operating expenses(111)
Operating loss:(111)
Nonoperating income
(Other Nonoperating income)
15
Net loss available to common stockholders, diluted:(96)

Comprehensive Income ($ in thousands)

6/30/2017
Net loss:(96)
Comprehensive loss, net of tax, attributable to parent:(96)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: